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MeOBJECTIVES The aim of this study was to analyze the incidence, impact, and predictors of cerebrovascular events
(CVEs) in patients undergoing transcatheter aortic valve replacement (TAVR).
BACKGROUND Several issues remain unresolved post-TAVR, including CVEs.
METHODS The FRANCE-2 (French Aortic Nation CoreValve and Edwards-2) registry prospectively included all patients
who underwent TAVR in France and Monaco from January 2010 to October 2011. A total of 3,191 patients were analyzed.
Six-month follow-up data were obtained. Events were adjudicated according to Valve Academic Research Consortium
(VARC)-1 deﬁnition.
RESULTS Of the cohort, 3.98% experienced a CVE: 55% were major strokes, 14.5% minor strokes, and 30.5% transient
ischemic attacks. The mean delay for CVE occurrence was 2 days (interquartile range: 0 to 7 days) with 48.5% of CVEs
occurring within 2 days. There was no statistically signiﬁcant difference in CVE rate with regard to the type of valve
(p ¼ 0.899) and the access route (p ¼ 0.128). Patients with a CVE more frequently had new-onset paroxysmal atrial
ﬁbrillation (13.6% vs. 7.6%; p ¼ 0.015). During follow-up, the unadjusted mortality rate was higher in patients with a
CVE (26% vs. 16.5%; p ¼ 0.002). By multivariate analysis, only advanced age (odds ratio: 1.05; 95% conﬁdence interval:
1.02 to 1.08; p ¼ 0.02) and having 2 valves implanted (odds ratio: 3.13; 95 conﬁdence interval: 1.40 to 7.05; p ¼ 0.006)
were associated with a signiﬁcant risk of CVEs.
CONCLUSIONS CVEs occur frequently after TAVR and are associated with an increased mortality rate. No difference
exists in the CVE rate when exploring the type of valve or the access route. Advanced age and multiple valves implanted
during the same procedure are predictors of CVE. (J Am Coll Cardiol Intv 2014;7:1138–45) © 2014 by the American
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1139AB BR E V I A T I O N S
AND ACRONYM S
CVE = cerebrovascular event
ES = Edwards SAPIEN
ESXT = Edwards SAPIEN XT
HITS = high-intensity transient
signal
MCV = Medtronic CoreValve
NIHSS = National Institutes of
Health Stroke Scale
TAVR = transcatheter aortic
valve replacement
TIA = transient ischemic attack
VARC = Valve Academic
arch ConsortiumT ranscatheter aortic valve implantation(TAVR) is a valid option for symptomatic pa-tients with aortic stenosis and deemed inop-
erable or at high risk for conventional surgery. TAVR
has proved to be superior to medical treatment for
inoperable patients and to be noninferior to surgery
in selected high-risk patients (1,2). Despite worldwide
growing experience, several TAVR-related issues
remain unresolved and insufﬁciently explored.
Among these issues, cerebrovascular events (CVEs)
are one of the most serious complications, poten-
tially affecting patient survival, autonomy, and qual-
ity of life. CVEs before and after TAVR may be
multifactorial and include embolic debris or
thrombus, aortic dissection, hemodynamic insta-
bility, and bleeding. The randomized PARTNER
(Placement of Aortic Transcatheter Valves) trial
raised concern about higher stroke rates post-TAVR
compared with medical therapy or surgical aortic
valve replacement (1,2). In other reports, stroke rates
range from 1.5% to 20% (3,4). The FRANCE-2 (French
Aortic National CoreValve and Edwards-2) registry
is the largest TAVR registry published thus far on
consecutive patients (5). We aimed to explore the
incidence, timing, impact, and predictors of CVEs in
this large cohort of patients.
METHODS
PATIENT SELECTION. The FRANCE-2 registry is a
prospective database that included all patients who
underwent TAVR from January 2010 to October 2011
at 33 selected French centers and 1 center in Monaco.
Patients were eligible for TAVR if they had a com-
bination of symptomatic severe aortic stenosis,
comorbidities contraindicating surgery or EuroSCORE
(Logistic European System for Cardiac Operative Risk
Evaluation) $20% or a Society of Thoracic Surgery
score $10%, and a life expectancy of >1 year. The ﬁnal
decision for TAVR and access route was made on the
basis of an on-site multidisciplinary heart team dis-
cussion. The FRANCE-2 registry was established
under the French Societies of Cardiology and Thoracic
and Cardiovascular Surgery. All patients provided
written informed consent before the procedure,
including consent for anonymous processing of theirproctoring fees from Edwards Lifesciences, Medtronic, and Boston Scientiﬁ
consultant for Medtronic and Boston Scientiﬁc. Dr. Himbert is a proctor and c
for Medtronic. Dr. Lievre has served on the Advisory Board of Novo Nordis
institutional grant fromMedtronic. All other authors have reported that they
paper to disclose.
Manuscript received January 13, 2014; revised manuscript received March 2data. The registry was approved by the insti-
tutional review board of the French Ministry
of Health. Valve manufacturers funded the
registry but did not have any role in data
collection or analysis or in the preparation of
the manuscript. All patients were followed at
1 month and 6 months and then annually for 5
years.
PROCEDURE. Each heart team could choose
to implant 1 of 2 commercially available
transcatheter aortic valves: the balloon-
expandable Edwards SAPIEN (ES) or SAPIEN
XT (ESXT) valves (Edwards Lifesciences,
Irvine, California) or the self-expandable
Medtronic CoreValve (MCV) and MCV Accu-
trak (Medtronic, Minneapolis, Minnesota). ES and
ESXT valves were implanted via the transfemoral,
transapical, or direct aortic routes, whereas the MCV
valves were implanted via the transfemoral, subcla-
vian, or direct aortic approaches. Procedures were
performed in a hybrid room (surgical operating room
with integrated ﬂuoroscopy and imaging modalities),
a catheterization laboratory, or a conventional oper-
ating room according to the policy of each center.
General anesthesia or conscious sedation were used
according to the heart team’s preference. Patients
were treated with aspirin and clopidogrel before the
procedure (aspirin alone before transapical or direct
aortic approaches). Unfractionated heparin was given
at the start of the procedure aiming at an activated
clotting time of 200 to 300 s. After TAVR, long-term
aspirin therapy (75 to 300 mg) was prescribed, and
clopidogrel was prescribed for 1 to 6 months accord-
ing to each center’s policy. For patients taking
warfarin, aspirin was added (75 to 300 mg) for 1 to 6
months according to each center’s preference.
DEFINITIONS OF A CVE. Valve Academic Research
Consortium (VARC)-1 deﬁnitions (6) were used. A CVE
was deﬁned as a rapid onset of a neurological deﬁcit.
No other readily identiﬁable nonstroke cause had
to be present at the clinical presentation.
The conﬁrmation of the diagnosis of stroke was
made by at least 1 of the following: neurological or
neurosurgical specialist, neuroimaging procedure
(magnetic resonance imaging, computed tomography,
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1140or cerebral angiography), or lumbar puncture (i.e.,
spinal ﬂuid analysis diagnostic of intracranial hemor-
rhage). CVEs were divided into 3 categories:
 Transient ischemic attack (TIA): new focal neuro-
logical deﬁcit with rapid symptom resolution,
always within 24 h. Neuroimaging without tissue
injury.
 Minor stroke: diagnosis as above with a modiﬁed
Rankin Scale score <2 at 7 days post diagnosis or
before discharge and National Institutes of Health
Stroke Scale (NIHSS) score <3 above baseline at 7
days or before discharge and at 30-day assessment.
 Major stroke: modiﬁed Rankin Scale score >2 at
7 days or before discharge and NIHSS score >3
above baseline at 7 days or before discharge and at
30-day assessment.TABLE 1 Baseline Characteristics of the Study Population
Total Population
(N ¼ 3,191)
Female, % 49.0
Age, yrs, % 84.1 (79.1–87.7)
<75 12.7
75–80 16.0
80–85 27.5
85–90 33.2
$90 10.7
NYHA functional class, %
I 1.6
II 22.5
III 62.5
IV 13.3
Valve area, cm2 0.67 (0.54–0.80)
Indexed valve area, cm2/m2 0.38 (0.32–0.45)
Mean gradient, mm Hg 46.6 (37.0–57.0)
Ejection fraction, % 55.0 (45.0–65.0)
Ejection fraction <40%, % 16.8
Mitral regurgitation grade >2, % 2.0
Chronic atrial ﬁbrillation, % 26.6
Pulmonary arterial pressure, mm Hg 44.0 (35.0–55.0)
EuroSCORE, % 18.9 (11.4–28.9)
STS score, % 10.0 (5.6–20.4)
Charlson Comorbidity Index 2.0 (1.0–3.0)
Hemoglobin, g/dl 12.0 (11.0–13.2)
Creatinine, mmol/l 98.0 (78.0–128.0)
Creatinine clearance <60 ml/min, % 9.6
Warfarin, % 24.8
Aspirin, % 57.8
Clopidogrel, % 29.7
Porcelain aorta, % 8.0
Peripheral vascular disease, % 28.5
Previous CVE, % 10.0
Hypertension, % 69.4
Values are % or median (interquartile range).
CVE ¼ cerebrovascular event; EuroSCORE ¼ Logistic European System for Cardiac Op
Thoracic Surgeons.If there was discordance between modiﬁed Rankin Scale
score and NIHSS score determinations of major versus
minor stroke, ﬁnal adjudication was made by a qualiﬁed
neurologist.
NEW-ONSET ATRIAL FIBRILLATION. After TAVR,
patients stayed in an intensive care unit for at least
2 days and then were followed with 24-h electrocar-
diographic monitoring until discharge.
During the hospital monitoring, new-onset parox-
ysmal atrial ﬁbrillation was deﬁned as a new episode
of atrial ﬁbrillation lasting >30 s but <1 day. New-
onset persisting atrial ﬁbrillation was deﬁned as a
new episode of atrial ﬁbrillation lasting >1 day.
During the outpatient clinic follow-up, new-onset
persisting atrial ﬁbrillation was deﬁned as a new
episode documented on 12-lead electrocardiography.Patients With CVEs
(n ¼ 127)
Patients Without CVEs
(n ¼ 3,064) p Value
59.1 48.6 0.020
85.5 (81.7–88.7) 84.0 (79.0–87.7) <0.001
7.1 12.9
9.4 16.3
31.5 27.4 0.011
34.6 33.1
17.3 10.4
1.6 1.6
19.8 22.6 0.273
59.5 62.7
19.0 13.1
0.67 (0.56–0.80) 0.67 (0.54–0.80) 0.832
0.39 (0.33–0.47) 0.38 (0.32–0.45) 0.280
48.0 (38.0–56.0) 46.0 (37.0–57.0) 0.742
54.5 (45.0–65.0) 55.0 (45.0–65.0) 0.641
11.1 17.1 0.080
0 2.0 0.175
24.0 26.7 0.503
45.0 (34.0–59.5) 44.0 (35.0–55.0) 0.526
20.2 (12.8–30.7) 18.8 (11.3–28.8) 0.254
10.4 (6.0–21.7) 10.0 (5.5–20.3) 0.434
2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.785
12.0 (10.8–13.0) 12.0 (11.0–13.2) 0.680
108.0 (80.0–129.0) 98.0 (78.0–128.0) 0.236
7.9 9.7 0.495
24.2 24.8 0.869
59.7 57.7 0.666
25.8 29.8 0.336
8.8 8.0 0.734
31.0 28.4 0.537
12.1 9.9% 0.419
73.4% 69.3% 0.327
erative Risk Evaluation; NYHA ¼ New York Heart Association; STS ¼ Society of
TABLE 2 Timing of the Occurrence of CVEs (Number of Days From the
Index Procedure)
Time From Date of Valve Placement
(in Calendar Days) n Mean  SD Median Range
Overall 131 22.9  59.5 2 0–422
Major stroke 72 21.3  52.8 1 0–249
Minor stroke 19 28.2  96.3 2 0–422
Transient ischemic attack 40 23.1  48.8 2 0–188
CVE ¼ cerebrovascular events.
FIGURE 1 Timing of Cerebrovascular Events
Number of days elapsed from the index procedure before the
occurrence of a cerebrovascular event.
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1141The follow-up modalities did not allow for identiﬁ-
cation of episodes of paroxysmal atrial ﬁbrillation.
STATISTICAL ANALYSIS. A total of 3,191 patients of
the 3,195 recorded in the FRANCE-2 registry were
included in the analysis (date of TAVR was not
reported for the 4 excluded patients). The study
population was divided into 2 groups: patients who
experienced a CVE during the follow-up period and
those who did not. Patient characteristics and details
of the procedure were described using summary sta-
tistics: median and interquartile range for continuous
variables, as none of them were normally distributed,
and frequencies and percentages for categorical var-
iables. Differences between the 2 groups were tested
using Wilcoxon rank sum test for continuous vari-
ables and the chi-square or Fisher exact test for the
categorical ones. Patient characteristics and details of
the procedure were explored as potential predictors
of occurrence of CVEs using logistic regression. Each
potential predictor was tested in a univariate model,
and those that were signiﬁcant (p # 0.05) were com-
bined in a multivariate model. The results of these
models are reported as odds ratios. Mortality was
analyzed using the Kaplan-Meier method. All ana-
lyses are performed using Stata SE version 8.2.
(StataCorp., College Station, Texas).
RESULTS
PATIENT CHARACTERISTICS. The baseline charac-
teristics of the study population are reported in
Table 1. Patients experiencing CVEs were older
(84.7  6 years vs. 82.6  7.2 years; p < 0.001). There
were signiﬁcantly more women experiencing CVEs
(59.1% vs. 48.6%; p ¼ 0.02). The patients without
CVEs more frequently had chronic atrial ﬁbrillation
(7.6% vs. 0.8%; p ¼ 0.004). There was no other dif-
ference at baseline between both groups of patients.
Of note, a history of stroke, porcelain aorta, and pe-
ripheral vascular disease were, respectively, observed
in 10%, 8%, and 28.5% of the population.
CEREBROVASCULAR EVENTS. Patients were fol-
lowed for an average of 5.2  4.7 months after TAVR
(median, 4.3 months), and 13% were followed for at
least 12 months. Of the cohort, 127 patients had a CVE
(3.98% of the population). A total of 123 patients had
1 event, and 4 patients had 2 events (3 patients with
2 major strokes and 1 patient with 2 TIAs). During
follow-up, 2.2% of the patients had a major stroke,
0.6% had a minor stroke, and 1.2% had a TIA. These
events occurred shortly after the procedure: 2 days
(range, 0 to 7 days) (Table 2, Figure 1). Most of CVEs
(48.5%) were diagnosed within 48 h after TAVR,whereas 36.9% occurred between 2 and 30 days and
14.6% after 1 month.
PROCEDURAL OUTCOME. Transfemoral access was
used in 74.6% of the population, and 66.9% of the
patients received ES or ESXT valves (Table 3). There
was no statistically signiﬁcant difference in stroke
rate with regard to the type of valve (p ¼ 0.07), the
transfemoral approach using the ES/ESXT or MCV
(p ¼ 0.968), or the procedural success rate (p ¼ 0.259).
For nontransfemoral access, there was no difference
between approaches (p ¼ 0.279). No signiﬁcant
difference was identiﬁed between groups of patients
with and without CVEs in terms of procedural details
except the need for multiple valves. In patients
experiencing CVEs, 2 valves were more often used
during the procedure (5.5% vs. 2.1%; p ¼ 0.012). There
were more patients requiring 2 MCVs than patients
treated with 2 ES/ESXTs (3.5% vs. 1.7%; p ¼ 0.001),
without any statistical difference in terms of the CVE
rate. Valve success was similar between patients with
and without CVEs (95.3% vs. 97%; p ¼ 0.259), despite
a higher rate of multiple valves used in the ﬁrst
group. The main reason for using a second valve was
TABLE 3 Procedure Details and Outcome
Total Population
(N ¼ 3,191)
Patients With
CVEs
(n ¼ 127)
Patients Without
CVEs
(n ¼ 3,064) p Value
Access, %
Transapical 17.8 18.9 17.8
Transfemoral 74.6 68.5 74.8 0.128
Subclavian 5.8 10.2 5.6
Direct aortic 1.8 2.4 1.8
Valve type, %
Medtronic CoreValve 17.5 19.8 17.4
Edwards SAPIEN 19.6 18.3 19.7 0.899
Edwards SAPIEN XT 47.3 46.0 47.4
Medtronic CoreValve
Accutrak
15.6 15.9 15.5
Procedural outcome, %
Implantation of 2 valves 2.3 5.5 2.1 0.012
Device success 97 95.3 97.0 0.259
Emergency conversion
in surgery
0.4 0.8 0.4 0.386
Post-procedural outcome
Length of ICU stay, days 3.0 (2.0–5.0) 3.0 (2.0–6.0) 3.0 (2.0–4.0) 0.001
Duration of hospitalization,
days
8.0 (6.0–12.0) 11.0 (7.0–16.5) 8.0 (6.0–12.0) <0.001
Major bleeding, % 4.6 10.2 4.4 0.002
Need for a permanent
pacemaker, %
13.1 10.2 13.3 0.324
New-onset paroxysmal
atrial ﬁbrillation, %
7.9 13.6 7.6 0.015
New-onset persisting
atrial ﬁbrillation, %
7.3 0.8 7.6 0.004
Values are median (interquartile range).
CVEs ¼ cerebrovascular events; ICU ¼ intensive care unit.
FIGURE 2 Kaplan-
One-year survival of a
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1142valve embolization resolved by either retrieval or
impaction in an extra-annular location.
POST-PROCEDURAL OUTCOME AND SURVIVAL.
The post-procedural outcome is detailed in Table 3.Meier Survival Curves
ll-cause mortality in patients with and without a cerebrovascular event.The length of intensive care unit stay and hospital
stay were signiﬁcantly longer for patients with CVEs
(4.9  5.1 days vs. 3.9  4.7 days, respectively; p ¼
0.018 and 13.2  9.5 days vs. 9.9  7.9 days; p <
0.001). During the in-hospital period, patients with
CVEs more frequently had new-onset paroxysmal
atrial ﬁbrillation (13.6% vs. 7.6%; p ¼ 0.015). During
the whole follow-up period, new-onset persisting
atrial ﬁbrillation occurred more frequently in patients
without CVEs (7.6% vs. 0.8%; p ¼ 0.004). Of patients
who had a neurological event, 26.0% died during the
follow-up period compared with 16.5% of patients
who did not (p ¼ 0.005). Kaplan-Meier survival
curves conﬁrmed a signiﬁcant and sustained increase
in all-cause unadjusted mortality rate in patients with
a CVE during follow-up (Figure 2).
PREDICTORS OF CVES. On univariate analysis,
female sex, older age, and 2 valves used in the same
patient were the only predictors of CVE after TAVR
(Table 4). On multivariate analysis, only advanced age
and 2 valves placed were associated with a signiﬁcant
risk of CVE (Table 5). Pacemaker implantation was
not associated with an increased risk of CVE (odds
ratio: 0.15; 95% conﬁdence interval: 0.05 to 0.47;
p ¼ 0.001).
DISCUSSION
The FRANCE 2 registry is, to our knowledge, one of
the largest prospective registries exploring CVEs.
These events occur frequently and have a negative
impact on the patient survival after TAVR.
The stroke rate reported in the FRANCE 2 is
concordant with data from the literature. Eggebrecht
et al. (3) performed a meta-analysis of 53 studies
including 10,037 patients and identiﬁed a stroke rate
of 5.2  3.4% during the ﬁrst year. The main limita-
tion of this analysis is the lack of uniformity in the
deﬁnitions used for stroke. Jilaihawi et al. (7)
analyzed the outcome of 5,024 patients who under-
went TAVR and found a stroke rate of 2.6% at 30 days.
Genereux et al. (8) performed another meta-analysis
of 16 studies reporting Valve Academic Research
Consortium outcomes and identiﬁed a 30-day risk of
major stroke of 3.2% (95% conﬁdence interval: 2.1% to
4.8%). In cohort A of the PARTNER 1 trial, rates of
stroke and TIA were higher among patients under-
going TAVR compared with surgical aortic valve
replacement at 30 days (4.6% vs. 2.4%; p ¼ 0.12) and
up to 2 years of follow-up (11.2% vs. 6.5%; p ¼ 0.05)
(9). In cohort B of the PARTNER 1 trial comparing
TAVR with medical treatment in inoperable patients,
the stroke/TIA rate was signiﬁcantly higher in
TABLE 4 Predictors of CVEs by Univariate Analysis
Predictor OR p Value 95% CI
Sex
Male 1.00 — —
Female 1.53 0.021 1.06–2.19
Age
Continuous: value for a
1-yr increment
1.05 0.002 1.02–1.08
Age group, yrs
0–75 1.00 — —
75–80 1.06 0.900 0.44–2.54
80–85 2.09 0.048 1.01–4.36
85–90 1.90 0.082 0.92–3.94
90þ 3.04 0.006 1.38–6.69
Creatinine clearance <60 ml/min
No 1.00 — —
Yes 0.80 0.496 0.41–1.54
Porcelain aorta
No 1.00 — —
Yes 1.12 0.734 0.59–2.10
Peripheral vascular disease
No 1.00 — —
Yes 1.13 0.537 0.77–1.66
Previous CVE
No 1.00 — —
Yes 1.26 0.420 0.72–2.18
Hypertension
No 1.00
Yes 1.22 0.328 0.82–1.84
NYHA functional class
I–II 1.00 — —
III–IV 1.17 0.470 0.76–1.81
Valve area
Continuous: value for a
1-cm2 increment
0.70 0.424 0.29–1.70
Indexed valve area
Continuous: value for a
1 cm2/m2 increment
1.02 0.619 0.94–1.11
Gradient
Continuous: value for a
1-mm Hg increment
1.00 0.769 0.99–1.01
Continued in the next column
TABLE 4 Continued
Predictor OR p Value 95% CI
LVEF <40%
No 1.00 — —
Yes 0.61 0.083 0.35–1.07
Chronic atrial ﬁbrillation
No 1.00 — —
Yes 0.87 0.504 0.57–1.32
EuroSCORE
Continuous: value for a
1-point increment
1.00 0.594 0.99–1.01
STS score
Continuous: value for a
1-point increment
1.00 0.564 0.99–1.02
2 Valves
No 1.00 — —
Yes 2.67 0.016 1.20–5.95
Access
Transapical 1.00 — —
Femoral 0.86 0.523 0.54–1.37
Subclavian 1.71 0.131 0.85–3.43
Direct aortic 1.25 0.723 0.36–4.29
Major bleeding
No 1.00 — —
Yes 1.47 0.305 0.70–3.07
CI ¼ conﬁdence interval; LVEF¼ left ventricular ejection fraction; OR ¼ odds ratio;
other abbreviations as in Tables 1 and 2.
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1143patients treated with TAVR: 6.7% vs. 1.7%, p ¼ 0 .02 at
30 days; 11.2 vs. 5.5%, p ¼ 0.06 at 1 year; and 13.8% vs.
5.5%, p ¼ 0.01 at 2 years of follow-up (10).
We could not precisely determine the ischemic or
hemorrhagic nature of the CVEs observed in the
FRANCE 2 because our database did not contain that
information. Nombela-Franco et al. (11) identiﬁed,
in a collaborative retrospective registry of 1,061 pa-
tients, hemorrhagic events in only 2 patients. Nuis
et al. (12) identiﬁed a 5% hemorrhagic stroke rate in a
single-center series of 214 patients treated with the
MCV. Therefore, the vast majority of TAVR-related
CVEs seem to be ischemic. More precisely, Makkar
et al. (10) analyzed the stroke rate at 2 years in
cohort B of the PARTNER trial and observed that thestroke rate was higher after TAVR than after medical
therapy (13.8% vs. 5.5%; p ¼ 0.01). In the ﬁrst
30 days, there were more ischemic CVEs after TAVR
(6.7% vs. 1.7%; p ¼ 0.02), and beyond 30 days, there
were more hemorrhagic CVEs after TAVR (2.2% vs.
0.6%; p ¼ 0.16).
We identiﬁed a period of stroke vulnerability,
extending to the ﬁrst month after TAVR with a mean
delay of occurrence of 22.9  59.5 days (median,
2 days). Almost half of the CVEs were acute and peri-
procedural events, occurring within 48 h after valve
replacement. This is consistent with ﬁndings of
Nombela-Franco et al. (11) and Nuis et al. (12), who
identiﬁed acute stroke (within 24 h) in, respectively,
54% and 42% of their patients. These acute events can
occur at various steps of the procedures, for example,
crossing the aortic valve, balloon valvuloplasty,
placement of the valve, deployment of the valve, and
withdrawal of the delivery system. Kahlert et al. (13)
performed an interesting study of serial transcranial
Doppler imaging in 83 patients to identify high-
intensity transient signals (HITSs) as a surrogate for
microembolization. Periprocedural HITSs were detec-
ted in all patients, mainly during manipulation across
the native aortic valve and implantation of stented
valves. The balloon-expandable ES valve caused
signiﬁcantly more HITSs during positioning and the
TABLE 5 Predictors of CVEs Identiﬁed by Multivariate Analysis
Predictor Modality OR p Value 95% CI
Age Continuous: value for a
1-yr increment
1.05 0.002 1.02–1.08
2 Valves No 1.00 — —
Yes 3.13 0.006 1.40–7.05
Pacemaker implantation
before the CVE
No 1.00 — —
Yes 0.15 0.001 0.05–0.47
Abbreviations as in Tables 1 and 4.
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Overall, there were no signiﬁcant differences between
transfemoral and transapical TAVR or between the
MCV and ES valve. In this series, only 1 subsequent
major stroke and 1 minor stroke were diagnosed.
CVEs are associated with an increased mortality. In
elderly and frail patients, stroke has a clear negative
impact on autonomy and quality of life. In a series of
389 patients, Stortecky et al. (14) reported that
patients with CVEs had an increased risk of all-cause
and cardiovascular mortality compared with patients
without CVEs at 30 days of follow-up. Nombela-
Franco et al. (11) conﬁrmed the same ﬁndings at
30-day and 1-year follow-up with major stroke and its
permanent functional disability being associated with
the worst outcome.
On multivariate analysis, age and multiple valves
used in the same procedure were predictors of CVEs.
Female sex was a predictor of CVEs only on univariate
analysis. A signiﬁcant proportion of CVEs associated
with female sex may be explained by bleeding. The
PRAGMATIC (Pooled-RotterdAM-Milano-Toulouse In
Collaboration) registry reported a higher stroke rate
in patients experiencing bleeding after TAVR and
identiﬁed female sex as a risk factor for bleeding and
transfusion. Complex procedures with multiple
valves may increase the risk of stroke by increasing
the risk of debris embolization. The embolic nature of
periprocedural stroke was elegantly demonstrated by
Van Mieghem et al. (15) by using a dual ﬁlter–based
embolic protection device in 40 patients undergoing
TAVR. Macroscopic material liberated during the
procedure was captured in the device ﬁlter baskets in
30 patients (75%), varying in size from 0.15 to 4.0 mm
and consisting of ﬁbrin or amorphous calcium and
connective tissue derived most likely from either
the native aortic valve leaﬂets or the aortic
wall. Although new-onset atrial ﬁbrillation was more
frequently observed in patients with CVEs, it was not
identiﬁed as a predictor of stroke in the FRANCE 2.
This event was mainly captured during in-hospital
monitoring, and its real frequency may beunderestimated because of the difﬁculty in recording
it during a longer follow-up with electrocardiograms
obtained only at 1 month, 6 months, and then yearly.
Interestingly, persisting atrial ﬁbrillation occurred
more frequently in patients without CVEs. One
explanation could be a more thorough and prolonged
anticoagulant treatment in those patients, most of the
time in combination with aspirin alone. Conversely, it
is likely that patients with new-onset atrial ﬁbrilla-
tion did not all receive adequate anticoagulant
treatment at the time of the event. Amat-Santos et al.
(16) recorded new-onset atrial ﬁbrillation during the
in-hospital follow-up in 31.9% of their TAVR patients.
Nombela-Franco et al. (11) identiﬁed post-dilation
balloon and valve dislodgment/embolization as pre-
dictors of acute CVEs (<24 h), whereas new-onset
atrial ﬁbrillation determined a higher risk for sub-
acute CVEs (1 to 30 days), and the number of late
events (>30 days) were higher in patients with a
history of chronic atrial ﬁbrillation, cerebrovascular
disease, and peripheral vascular disease. Pacemaker
implantation was not associated with an increased
risk of CVEs. Only 3 patients experienced the
sequence of having a pacemaker and then a CVE
during follow-up. Potential explanations could be a
sustained sinus rhythm after pacemaker placement or
a more meticulous assessment and management of
rhythm disturbances (e.g., new-onset atrial ﬁbrilla-
tion) in patients receiving a pacemaker.
Considering these risk factors for CVEs, protective
maneuvers could be associated with the use of an
embolic protection device, limiting manipulation
across the native aortic valve, avoiding balloon
valvuloplasty, maintaining effective anticoagulant
treatment, or using antiarrhythmic drugs in the
stroke vulnerability period post-TAVR. The antico-
agulant treatment should be tailored to the bleeding
risk of each patient because bleeding and transfusion
have been reported to carry an intrinsic increased risk
of stroke (17).
STUDY LIMITATIONS. There was no central core
laboratory adjudication of the events. CVEs and other
complications were reported by each participating
heart team.
Several predictors of neurological events could not
be explored because they were not collected in the
database. The type of anticoagulant treatment at the
time of stroke was not consistently reported. The use
of Valve Academic Research Consortium 2 deﬁnitions
was not retrospectively possible because the FRANCE
2 database does not contain modiﬁed Rankin Scale
scores at 90 days. The follow-up at the time of the
analysis was relatively short and will be extended by
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11455 years to provide more robust results of the FRANCE
2 registry.
CONCLUSIONS
CVEs occur frequently after TAVR and mainly occur
within 48 h, with a stroke vulnerability period
extending to 1 month post-procedure. These events
are associated with an increased unadjusted mortalityrate. No difference exists in the CVE rate with regard
to the type of valve or the access route. Advanced age
and multiple valves used during the same procedure
are predictors of CVEs.
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